Quinolone antibiotics in the gastrointestinal lumen

Quinolone antibiotics in the gastrointestinal lumen represent a therapeutic target for agents designed to protect the gut microbiome from the collateral damage of systemic antibiotic therapy [1, 2]. While quinolones are intended to treat systemic or localized infections, their residual presence in the lower gastrointestinal tract can lead to dysbiosis, the emergence of antibiotic-resistant bacteria, and opportunistic infections such as Clostridioides difficile [2, 3]. Therapeutic strategies, such as the use of specialized adsorbents like DAV132, aim to sequester these residual antibiotics in the late ileum and colon [1, 5]. By neutralizing the quinolones before they can affect the colonic microbiota, these interventions help maintain microbial diversity and prevent the selection of resistant strains without compromising the systemic efficacy of the antibiotic treatment [1, 8]. This approach is particularly relevant for fluoroquinolones, which are known for their broad-spectrum activity and significant impact on the gut's anaerobic and aerobic commensal populations [2, 9].

Other names

Residual gastrointestinal quinolonesIntraluminal quinolonesFecal quinolonesGastrointestinal fluoroquinolones

Sequestration and adsorption of residual antibiotic molecules within the gastrointestinal lumen to prevent their interaction with the commensal microbiota.